missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Protein Analysis Reagents
  4. Bioactive Small Molecules
  5. Tocris Bioscience™ AZD 4547

Tocris Bioscience™ AZD 4547

Product Code. 18718386
Click to view available options
Quantity:
10 mg
50 mg
Unit Size:
10mg
50mg
This item is not returnable. View return policy

Product Code. 18718386

Brand: Tocris Bioscience™ 7823/50

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Potent and selective FGFR inhibitor

AZD 4547 is a potent and selective FGFR1, FGFR3 and FGFR2 tyrosine kinase inhibitor (IC50 values are 0.2 1.8, and 2.5 nM, respectively). It shows selectivity for FGFR across a range of unrelated tyrosine and serine/threonine kinases, including IGFR (>2,900-fold), CDK2 (>50,000-fold), and p38 (>50,000-fold). In vitro, it has antiproliferative effects on tumor cell lines with deregulated FGFR expression. In vivo, AZD 4547 exhibits dose-dependent inhibition of tumor growth in an FGFR-driven human tumor xenograft mice model. It suppresses osteoclastogenesis and tumor-induced osteolysis in an orthotopic breast cancer bone metastasis mouse model. AZD 4547 is orally bioavailable.
TRUSTED_SUSTAINABILITY

Specifications

Chemical Name or Material rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide
CAS 1035270-39-3
Quantity 50 mg
Target FGF Receptor Inhibitors
Molecular Formula C26H33N5O3
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.